(AKE) Arkema - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: PA (France) | Market Cap: 4.741m EUR | Total Return: -5.5% in 12m
Specialty Polyamides, Adhesives, Fluorogases, Coating Resins, Peroxides
Total Rating 35
Safety 68
Buy Signal -0.23
Specialty Chemicals
Industry Rotation: -3.4
Industry Rotation: -3.4
Market Cap:
5.51B
Avg Turnover: 12.8M
Avg Turnover: 12.8M
Risk 3d forecast
Volatility31.6%
VaR 5th Pctl5.41%
VaR vs Median4.09%
Reward TTM
Sharpe Ratio-0.10
Rel. Str. IBD38.5
Rel. Str. Peer Group34.5
Character TTM
Beta0.445
Beta Downside0.550
Hurst Exponent0.497
Drawdowns 3y
Max DD48.40%
CAGR/Max DD-0.15
CAGR/Mean DD-0.33
EPS (Earnings per Share)
EPS CAGR: -40.51%
EPS Trend: -76.7%
EPS Trend: -76.7%
Last SUE: 0.14
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -9.59%
Rev. Trend: -78.1%
Rev. Trend: -78.1%
Last SUE: 0.49
Qual. Beats: 0
Qual. Beats: 0
Warnings
P/E ratio 122.8
Below Avwap Earnings
Tailwinds
No distinct edge detected
Description: AKE Arkema
Arkema S.A. is a French specialty materials manufacturer operating through three primary segments: Adhesive Solutions, Advanced Materials, and Coating Solutions. The company produces a wide array of high-performance polymers, surfactants, and resins used across the construction, automotive, electronics, and renewable energy sectors. Its portfolio focuses on high-value applications such as 3D printing materials, bio-based polymers, and lightweighting solutions for the transportation industry.
The specialty chemicals sector is characterized by high R&D intensity and a shift toward sustainable chemistries to meet evolving environmental regulations. Arkemas business model relies on a global manufacturing footprint to serve diverse markets including decorative paints, industrial coatings, and hygiene products. You can examine detailed valuation metrics and historical performance for Arkema on ValueRay to further inform your analysis. The company maintains a significant presence in the fluorogases and acrylics markets, positioning it as a key supplier for the refrigeration and water treatment industries.
- Shift toward high-margin specialty materials improves group profitability and valuation multiples
- Fluctuating raw material costs and energy prices impact industrial segment margins
- Global construction and automotive demand cycles dictate volume growth across core segments
- Stringent environmental regulations on fluorinated gases pose long-term structural transition risks
- Expansion in battery materials and bio-based polymers drives future revenue growth potential
Piotroski VR‑10 (Strict)
4.0
| Net Income: 41.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.00 > 1.0 |
| NWC/Revenue: 30.28% < 20% (prev 27.12%; Δ 3.16% < -1%) |
| CFO/TA 0.07 > 3% & CFO 983.6m > Net Income 41.3m |
| Net Debt (3.34b) to EBITDA (918.7m): 3.64 < 3 |
| Current Ratio: 2.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.9m) vs 12m ago -0.08% < -2% |
| Gross Margin: 17.56% > 18% (prev 0.20%; Δ 1.74k% > 0.5%) |
| Asset Turnover: 62.19% > 50% (prev 67.01%; Δ -4.82% > 0%) |
| Interest Coverage Ratio: 1.61 > 6 (EBITDA TTM 918.7m / Interest Expense TTM 130.0m) |
Altman Z''
3.02
| A: 0.19 (Total Current Assets 4.84b - Total Current Liabilities 2.15b) / Total Assets 14.22b |
| B: 0.31 (Retained Earnings 4.41b / Total Assets 14.22b) |
| C: 0.01 (EBIT TTM 209.0m / Avg Total Assets 14.26b) |
| D: 0.64 (Book Value of Equity 5.07b / Total Liabilities 7.88b) |
| Altman-Z'' Score: 3.02 = A |
Beneish M
-3.12
| DSRI: 0.92 (Receivables 1.48b/1.73b, Revenue 8.87b/9.58b) |
| GMI: 1.14 (GM 17.56% / 19.95%) |
| AQI: 0.94 (AQ_t 0.38 / AQ_t-1 0.41) |
| SGI: 0.93 (Revenue 8.87b / 9.58b) |
| TATA: -0.07 (NI 41.3m - CFO 983.6m) / TA 14.22b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of AKE shares?
As of May 21, 2026, the stock is trading at EUR 60.55 with a total of 362,140 shares traded.
Over the past week, the price has changed by -5.17%, over one month by -2.34%, over three months by +0.17% and over the past year by -5.49%.
Over the past week, the price has changed by -5.17%, over one month by -2.34%, over three months by +0.17% and over the past year by -5.49%.
Is AKE a buy, sell or hold?
Arkema has no consensus analysts rating.
What are the forecasts/targets for the AKE price?
| Analysts Target Price | - | - |
Arkema (AKE) - Fundamental Data Overview
as of 19 May 2026
Market Cap USD = 5.51b (4.74b EUR * 1.1625 EUR.USD)P/E Trailing = 122.8431
P/E Forward = 13.6426
P/S = 0.5346
P/B = 0.6973
P/EG = 0.4673
Revenue TTM = 8.87b EUR
EBIT TTM = 209.0m EUR
EBITDA TTM = 918.7m EUR
Long Term Debt = 3.51b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 465.3m EUR (from shortTermDebt, last quarter)
Debt = 5.07b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.34b EUR (from netDebt column, last quarter)
Enterprise Value = 8.09b EUR (4.74b + Debt 5.07b - CCE 1.73b)
Interest Coverage Ratio = 1.61 (Ebit TTM 209.0m / Interest Expense TTM 130.0m)
EV/FCF = 20.21x (Enterprise Value 8.09b / FCF TTM 400.0m)
FCF Yield = 4.95% (FCF TTM 400.0m / Enterprise Value 8.09b)
FCF Margin = 4.51% (FCF TTM 400.0m / Revenue TTM 8.87b)
Net Margin = 0.47% (Net Income TTM 41.3m / Revenue TTM 8.87b)
Gross Margin = 17.56% ((Revenue TTM 8.87b - Cost of Revenue TTM 7.31b) / Revenue TTM)
Gross Margin QoQ = 17.60% (prev 14.82%)
Tobins Q-Ratio = 0.57 (Enterprise Value 8.09b / Total Assets 14.22b)
Interest Expense / Debt = 0.57% (Interest Expense 29.0m / Debt 5.07b)
Taxrate = 37.19% (16.7m / 44.9m)
NOPAT = 131.3m (EBIT 209.0m * (1 - 37.19%))
Current Ratio = 2.25 (Total Current Assets 4.84b / Total Current Liabilities 2.15b)
Debt / Equity = 0.82 (Debt 5.07b / totalStockholderEquity, last quarter 6.16b)
Debt / EBITDA = 3.64 (Net Debt 3.34b / EBITDA 918.7m)
Debt / FCF = 8.36 (Net Debt 3.34b / FCF TTM 400.0m)
Total Stockholder Equity = 6.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.29% (Net Income 41.3m / Total Assets 14.22b)
RoE = 0.62% (Net Income TTM 41.3m / Total Stockholder Equity 6.66b)
RoCE = 2.05% (EBIT 209.0m / Capital Employed (Equity 6.66b + L.T.Debt 3.51b))
RoIC = 1.36% (NOPAT 131.3m / Invested Capital 9.65b)
WACC = 3.83% (E(4.74b)/V(9.82b) * Re(7.55%) + D(5.07b)/V(9.82b) * Rd(0.57%) * (1-Tc(0.37)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 22.47 | Cagr: 0.11%
[DCF] Terminal Value 84.55% ; FCFF base≈343.6m ; Y1≈292.2m ; Y5≈224.1m
[DCF] Fair Price = 45.67 (EV 6.80b - Net Debt 3.34b = Equity 3.46b / Shares 75.7m; r=6.0% [WACC]; 5y FCF grow -18.17% → 3.0% )
EPS Correlation: -76.70 | EPS CAGR: -40.51% | SUE: 0.14 | # QB: 0
Revenue Correlation: -78.14 | Revenue CAGR: -9.59% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.54 | Chg30d=-7.42% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.35 | Chg30d=-8.17% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=4.73 | Chg30d=-0.67% | Revisions=+9% | GrowthEPS=+9.6% | GrowthRev=+0.3%
EPS next Year (2027-12-31): EPS=5.94 | Chg30d=+1.68% | Revisions=+14% | GrowthEPS=+25.5% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +33%